Connective tissue diseases

SAPHNELO (anifrolumab) Approved in the US for Moderate to Severe Systemic Lupus Erythematosus

Retrieved on: 
Monday, August 2, 2021

AstraZenecas SAPHNELO (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.

Key Points: 
  • AstraZenecas SAPHNELO (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
  • SAPHNELO is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.
  • Limitations of Use: The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus.
  • The Companys growing presence in immunology is focused on five mid- to late-stage franchises with multi-disease potential, in areas including rheumatology (including systemic lupus erythematosus), dermatology, gastroenterology, and systemic eosinophilic-driven diseases.

Newly Approved Lupus Drug Based on Discoveries Made in HSS Lab

Retrieved on: 
Monday, August 2, 2021

Much of the groundwork for the development of this drug was done in laboratories at Hospital for Special Surgery (HSS) in the early 2000s.

Key Points: 
  • Much of the groundwork for the development of this drug was done in laboratories at Hospital for Special Surgery (HSS) in the early 2000s.
  • In lupus, however, this receptor is activated even when no infection is present, causing the immune system to instead attack its host.
  • In the lab, Dr. Crow and her team began studying the blood of people with lupus and comparing it to the blood of healthy individuals.
  • In 2003, Dr. Crow and her HSS team were one of three groups to publish research confirming interferon's pivotal role in lupus.

Lupus Foundation of America Celebrates FDA Approval of Saphnelo™ (Anifrolumab-fnia) as a New Treatment for Lupus

Retrieved on: 
Monday, August 2, 2021

It is the third U.S. FDA approval of a lupus therapy since 2011, expanding treatment options for this medically underserved and life-threatening autoimmune disease.

Key Points: 
  • It is the third U.S. FDA approval of a lupus therapy since 2011, expanding treatment options for this medically underserved and life-threatening autoimmune disease.
  • With the approval of Saphnelo, we now have one more drug that allows us to translate valuable research knowledge into clinical practice with multiple benefits for our patients with lupus."
  • Saphnelo showed benefits on overall lupus disease activity, skin lupus and joints and the ability to taper down steroid doses.
  • The Lupus Foundation of America's research during the 1980s contributed to the development of Saphnelo through its support of research on interferons.

Scipher Medicine Increases Patient Access for Prismra® by Expanding Intended Use in Autoimmune Patients

Retrieved on: 
Thursday, July 29, 2021

WALTHAM, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with most effective therapy, today announced the expanded clinical utility and intended use to include most rheumatoid arthritis (RA) patients for its commercially available PrismRA blood test.

Key Points: 
  • WALTHAM, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with most effective therapy, today announced the expanded clinical utility and intended use to include most rheumatoid arthritis (RA) patients for its commercially available PrismRA blood test.
  • PrismRA is a first-of-its-kind molecular signature test that informs personalized treatment decisions for RA patients at any point in the clinical journey.
  • PrismRA, a molecular signature test, is a revolutionary advancement bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally.
  • We partner with payers, providers, and pharma along the healthcare value chain to bring precision medicine to autoimmune diseases.

AVISE® Lupus Test Demonstrates Statistically Significant Clinical Utility in Achieving a Definitive SLE Diagnosis and Positively Impacts Treatment Decisions

Retrieved on: 
Tuesday, July 13, 2021

This multi-center study demonstrated that the AVISE Lupus test helped increase confidence in ruling-in and ruling-out systemic lupus erythematosus (SLE) in patients suspected of this disease and informed appropriate treatment decisions.

Key Points: 
  • This multi-center study demonstrated that the AVISE Lupus test helped increase confidence in ruling-in and ruling-out systemic lupus erythematosus (SLE) in patients suspected of this disease and informed appropriate treatment decisions.
  • Assessment of the confidence in the diagnosis of SLE and initiation of hydroxychloroquine (HCQ) showed that the AVISE Lupus test impacted physician behavior.
  • In particular, physician certainty in an SLE diagnosis increased with increasing AVISE Lupus scores.
  • Similarly, certainty in an SLE diagnosis decreased when an AVISE Lupus score was negative, indicating that the test helped in both ruling-in and in ruling-out the disease.

Global Sjogren's Syndrome Acids Market (2020 to 2026) - Featuring AbbVie, Amgen and Biogen Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021

Sjogren also affects the other parts of the body such as kidneys, joints, lungs, nerves, blood vessels.

Key Points: 
  • Sjogren also affects the other parts of the body such as kidneys, joints, lungs, nerves, blood vessels.
  • The factors contributing to the market growth include a growing population with several diseases that can cause Sjogren's syndrome and increasing demand for advanced treatment for Sjogren's syndrome.
  • However, a lack of awareness among the population about Sjogren's syndrome restrains the growth of the market.
  • market.

Scipher Medicine Announces PrismRA® Met Primary and Secondary Endpoints in Prospective Observational Study Predicting Inadequate Response to World’s Largest-Selling Drug Class

Retrieved on: 
Thursday, June 24, 2021

PrismRA is the leading molecular signature test to help guide personalized therapy selection for rheumatoid arthritis.

Key Points: 
  • PrismRA is the leading molecular signature test to help guide personalized therapy selection for rheumatoid arthritis.
  • The NETWORK-004 study met primary and secondary endpoints, with a molecular signature of non-response detected in 45% of therapy-nave patients and 40% of patients who have already started TNFi therapy.
  • Most rheumatoid arthritis patients are prescribed the worlds largest selling drug class, TNFi therapy, yet the majority will not have an adequate response, said Alif Saleh, CEO Scipher Medicine.
  • We partner with payers, providers, and pharma along the health care value chain to bring precision medicine to autoimmune diseases.

Corrective Exercise Book "Built from Broken" Promises to Help Rebuild Joints and Relieve Pain Naturally

Retrieved on: 
Friday, June 18, 2021

PALM CITY, Fla., June 18, 2021 /PRNewswire/ --A book published by therapeutic sports nutrition company, SaltWrap, promises to help relieve joint pain and rebuild connective tissuesnaturally.

Key Points: 
  • PALM CITY, Fla., June 18, 2021 /PRNewswire/ --A book published by therapeutic sports nutrition company, SaltWrap, promises to help relieve joint pain and rebuild connective tissuesnaturally.
  • "We have much more control over how our joints adapt to physical stimuli than most people realize," said Scott Hogan, author of "Built from Broken" and Certified Orthopedic Exercise Specialist.
  • "Just like muscles, our joints are constantly going through a process of breakdown and repair.
  • Part 2 provides a complete overarching exercise plan to heal painful joints and build a strong, functional body that stands the test of time.

$4.7 Billion Autoimmune Diseases Diagnostics Global Market to 2026 - Technological Innovation in the Form of Lab Automation Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 16, 2021

The "Global Autoimmune Diseases Diagnostics Market (2021-2026) by Product, Test Type, Disease, End-user, Geography and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Autoimmune Diseases Diagnostics Market (2021-2026) by Product, Test Type, Disease, End-user, Geography and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • An autoimmune disease is a disorder wherein one's immune system attacks the body and destroys its body tissue.
  • There have been around 80 different types of autoimmune disorders being identified, of which, multiple sclerosis, type 1 diabetes, rheumatoid arthritis are fairly common.
  • Factors such as a rise in the incidence of autoimmune diseases have been a major driver for the growth of the market of autoimmune drugs.

Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test

Retrieved on: 
Tuesday, June 15, 2021

The study compared baseline PrismRA results with actual outcomes at six months using EULAR good response as the clinical outcome measure.

Key Points: 
  • The study compared baseline PrismRA results with actual outcomes at six months using EULAR good response as the clinical outcome measure.
  • The study found a EULAR-based inadequate response in 37 out of the 68 patients, or 54.4%.
  • The successful validation of the novel test for EULAR inadequate response in this treat-to-target setting is promising, said Johanna Withers , Ph.D., study co-author, and Principal Scientist at Scipher Medicine.
  • PrismRA, a molecular signature test, is a revolutionary advancement bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally.